| Perlmart Of Fischer Blvd Inc | |
| 860 Fischer Blvd, Toms River, New Jersey 08753 | |
| (732) 270-0900 |
| Name | Perlmart Of Fischer Blvd Inc |
|---|---|
| Organization Name | Perlmart Of Fischer Blvd Inc |
| Location | 860 Fischer Blvd, Toms River, New Jersey 08753 |
| Type | Pharmacy |
| Phone | (732) 270-0900 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.
BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria.
Sanofi-aventis announced today a strategic alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program.
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
› Verified 7 days ago
| NPI Number | 1770698540 |
| Organization Name | SAKER SHOPRITES INC |
| Doing Business As | SHOPRITE PHARMACY #610 |
| Type | Pharmacy |
| Address | 860 Fischer Blvd, Toms River, NJ 08753 |
| Phone Number | 732-270-0900 |
News Archive
BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.
BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria.
Sanofi-aventis announced today a strategic alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program.
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
› Verified 7 days ago
News Archive
BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.
BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria.
Sanofi-aventis announced today a strategic alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program.
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
› Verified 7 days ago
Cvs Phaarmacy # 02837 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1795 Hooper Ave, Toms River, New Jersey 08753 Phone: (732) 279-1431 | |
Rite Aid Pharmacy 10512 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 811 Fischer Blvd, Toms River, New Jersey 08753 Phone: (732) 929-3440 | |
Rite Aid Pharmacy 10515 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 220 Route 70, Toms River, New Jersey 08755 Phone: (732) 942-9469 | |
Rite Aid Pharmacy 10513 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2 Route 37 E, Toms River, New Jersey 08753 Phone: (732) 341-0022 | |
Rite Aid Pharmacy 10514 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1726 Route 37 E, Toms River, New Jersey 08753 Phone: (732) 929-1199 |